Bruderman Asset Management’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-3,192
Closed -$282K 112
2019
Q3
$282K Buy
3,192
+134
+4% +$12K 0.07% 105
2019
Q2
$279K Sell
3,058
-1,563
-34% -$132K 0.07% 97
2019
Q1
$398K Sell
4,621
-411
-8% -$33K 0.09% 100
2018
Q4
$387K Buy
5,032
+1,060
+27% +$82.5K 0.1% 94
2018
Q3
$307K Sell
3,972
-2,230
-36% -$165K 0.07% 98
2018
Q2
$420K Sell
6,202
-3,438
-36% -$237K 0.1% 96
2018
Q1
$698K Sell
9,640
-301
-3% -$22.9K 0.17% 86
2017
Q4
$748K Sell
9,941
-1,496
-13% -$113K 0.19% 80
2017
Q3
$880K Sell
11,437
-36,862
-76% -$2.78M 0.23% 74
2017
Q2
$3.61M Sell
48,299
-40,502
-46% -$2.87M 0.96% 33
2017
Q1
$5.91M Sell
88,801
-6,664
-7% -$444K 1.71% 20
2016
Q4
$6.23M Sell
95,465
-2,992
-3% -$194K 1.88% 18
2016
Q3
$6.97M Sell
98,457
-799
-0.8% -$58.2K 2.08% 14
2016
Q2
$7.34M Buy
99,256
+88,735
+843% +$6.13M 2.3% 13
2016
Q1
$683K Buy
10,521
+10,117
+2,504% +$688K 0.24% 73
2015
Q4
$31K Hold
404
0.01% 252
2015
Q3
$33K Buy
404
+147
+57% +$13.1K 0.01% 241
2015
Q2
$23K Hold
257
0.01% 289
2015
Q1
$23K Buy
+257
New +$22.8K 0.01% 284

Other funds holding NVS

Bruderman Asset Management's NVS Position: Q4 2019 in Review

Bruderman Asset Management sold out of Novartis (NVS) in Q4 2019, closing a stake of 3,192 shares — an estimated $282K sold.

Bruderman Asset Management first reported a position in NVS in Q1 2015 and held it in 19 quarters. The position peaked at $7.34M in Q2 2016. 1,172 funds tracked by Wall St. Rank hold NVS as of Q4 2019.

  • Bruderman Asset Management reported no remaining Novartis position as of Q4 2019 after selling out during the quarter.
  • Bruderman Asset Management sold 3,192 Novartis shares in Q4 2019, an estimated $282K.
  • Bruderman Asset Management first reported a position in Novartis in Q1 2015 and held it in 19 quarters.
  • Bruderman Asset Management's Novartis position peaked at $7.34M in Q2 2016.
  • 1,172 funds tracked by Wall St. Rank held Novartis as of Q4 2019.

Based on Bruderman Asset Management's 13F filing for Q4 2019, filed 13 Feb 2020.